How Direct-To-Consumer Television Advertising For Osteoarthritis Drugs Affects Physicians’ Prescribing Behavior
Open Access
- 1 September 2006
- journal article
- Published by Health Affairs (Project Hope) in Health Affairs
- Vol. 25 (5), 1371-1377
- https://doi.org/10.1377/hlthaff.25.5.1371
Abstract
Concern about the potential pernicious effect of direct-to-consumer (DTC) drug advertising on physicians’ prescribing patterns was heightened with the 2004 withdrawal of Vioxx, a heavily advertised treatment for osteoarthritis. We examine how DTC advertising has affected physicians’ prescribing behavior for osteoarthritis patients. We analyzed monthly clinical information on fifty-seven primary care practices during 2000–2002, matched to monthly brand-specific advertising data for local and network television. DTC advertising of Vioxx and Celebrex increased the number of osteoarthritis patients seen by physicians each month. DTC advertising of Vioxx increased the likelihood that patients received both Vioxx and Celebrex, but Celebrex ads only affected Vioxx use.Keywords
This publication has 8 references indexed in Scilit:
- Consumers' Reports On The Health Effects Of Direct-To-Consumer Drug AdvertisingHealth Affairs, 2003
- Direct‐to‐Consumer Advertising and the Demand for Cholesterol‐Reducing DrugsThe Journal of Law and Economics, 2002
- Patient autonomy and the regulation of direct-to-consumer advertisingClinical Therapeutics, 2001
- Risk of Cardiovascular Events Associated With Selective COX-2 InhibitorsJama-Journal Of The American Medical Association, 2001
- Mitigating Agency Problems by Advertising, with Special Reference to Managed Health CareSouthern Economic Journal, 1999
- Advertising and Competition in the Ethical Pharmaceutical Industry: The Case of Antihypertensive DrugsThe Journal of Law and Economics, 1999
- Direct to You: TV Drug Ads That Make SensePublished by American Psychological Association (APA) ,1998
- Matching Prescription Drugs and ConsumersNew England Journal of Medicine, 1985